A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

Wang-Da Liu; Po‐Hao Feng; Chien‐Yu Cheng; Chun-Liang Chou; Chih‐Hsin Lee; Min‐Chi Lu; Po‐Yu Liu; Mei-Hui Lee; Chun‐Hsing Liao; Mei-Chuan Chen; Cheng‐Pin Chen; Shang-Fu Hsu; Yu-Tien Tzeng; Yi-Chun Lin; Tsong‐Yih Ou; Albert Qin; Chan‐Yen Tsai; Weichung Joe Shih; Kang‐Yun Lee; Wang‐Huei Sheng

doi:10.1007/s40121-024-00992-5

Abstract

Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e69238b6db6435876193e1 https://doi.org/10.1007/s40121-024-00992-5

View Full Paper

Ask AI

Bookmark

Abstract

Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection.

A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

Abstract

Discussion

Cite This Study

A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19

Abstract

Discussion

Cite This Study

Keep reading

Keep reading